I just re-listened to portions of it. Partnering/licensing for all non-HIV indications were the ones currently in the data room. NP said they they said they would be giving an offer, but he obviously doesn't know if they will.
This means cancer, NASH, GvHD, MS, etc. could come into play pretty soon! That could be huge numbers even if only 15%+ royalty being Phase 2 indications.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.